CLAIMS

1. A compound represented by the formula (I):



(I)

wherein W represents



and R^3, R^7, R^{16}, R^{17}, R^{20}, R^{21} and $R^{21'}$, the same or different, independently represent

1) a hydrogen atom,

2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R^3 or R^7 in combination with a carbon atom to which R^3 or R^7 is bonded, and an oxo group formed by R^{21} and $R^{21'}$ together in combination with the carbon atom to which R^{21} and $R^{21'}$ are bonded,

3) a C_1 to C_{22} alkoxy group which may have a substituent,

4) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

5) a C_7 to C_{22} aralkyloxy group which may have a substituent,

6) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

7) RC(=Y)-O-, wherein Y represents an oxygen atom or sulfur atom, and R represents

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

d) a C_6 to C_{14} aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C_7 to C_{22} aralkyl group which may have a substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a C_1 to C_{22} alkoxy group which may have a substituent,

i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

j) a C_6 to C_{14} aryloxy group which may have a substituent,

k) a C_3 to C_{14} cycloalkyl group which may have a substituent,

l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

8) $R^{S1}R^{S2}R^{S3}SiO$-, wherein R^{S1}, R^{S2} and R^{S3}, the same or

different, independently represent

a) a C_1 to C_6 alkyl group or

b) a C_6 to C_{14} aryl group,

9) a halogen atom,

10) $R^{N1}R^{N2}N-R^M-$, wherein R^M represents

a) a single bond,

b) -CO-O-,

c) $-SO_2-O-$,

d) -CS-O- or

e) $-CO-NR^{N3}-$, wherein R^{N3} represents a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom,

R^{N1} and R^{N2}, the same or different, independently represent

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

d) an aliphatic C_2 to C_{22} acyl group which may have a substituent,

e) an aromatic C_7 to C_{15} acyl group which may have a substituent,

f) a C_6 to C_{14} aryl group which may have a substituent,

g) a 5-membered to 14-membered heteroaryl group which may have a substituent,

h) a C_7 to C_{22} aralkyl group which may have a substituent,

i) a C_1 to C_{22} alkylsulfonyl group which may have a substituent,

j) a C_6 to C_{14} arylsulfonyl group which may have a substituent,

k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

m) a C_3 to C_{14} cycloalkyl group which may have a substituent or

n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) $R^{N4}SO_2$-O-, wherein R^{N4} represents

a) a C_1 to C_{22} alkyl group which may have a substituent,

b) a C_6 to C_{14} aryl group which may have a substituent,

c) a C_1 to C_{22} alkoxy group which may have a substituent,

d) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

e) a C_6 to C_{14} aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C_7 to C_{22} aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

12) $(R^{N5}O)_2PO-O-$, wherein R^{N5} represents

a) a C_1 to C_{22} alkyl group which may have a substituent,

b) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

c) a C_6 to C_{14} aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,

e) a C_7 to C_{22} aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

13) $(R^{N1}R^{N2}N)_2PO-O-$, wherein R^{N1} and R^{N2} are the same as defined above or

14) $(R^{N1}R^{N2}N)(R^{N5}O)PO-O-$, wherein R^{N1}, R^{N2} and R^{N5} are the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate of those.

2. The compound according to claim 1 represented by the formula (I-a):



(I-a)

wherein W is the same as defined above, and R^{3a}, R^{7a}, R^{16a}, R^{17a}, R^{20a}, R^{21a} and $R^{21a'}$, the same or different, independently represent

1) a hydrogen atom,

2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R^{3a} or R^{7a} in combination with the carbon atom to which R^{3a} or R^{7a} is bonded, and an oxo group formed by R^{21a} and $R^{21a'}$ together in combination with a carbon atom to which R^{21a} and $R^{21a'}$ are bonded,

3) a C_1 to C_{22} alkoxy group which may have a substituent,

4) $R^aC(=Y^a)-O-$, wherein Y^a represents an oxygen atom or sulfur atom, and R^a represents

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

d) a C_6 to C_{14} aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C_7 to C_{22} aralkyl group which may have a substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a C_1 to C_{22} alkoxy group which may have a substituent,

i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

j) a C_6 to C_{14} aryloxy group which may have a substituent,

k) a C_3 to C_{14} cycloalkyl group which may have a substituent,

l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

5) $R^{aS1}R^{aS2}R^{aS3}SiO-$, wherein R^{aS1}, R^{aS2} and R^{aS3}, the same or different, independently represent

a) a C_1 to C_6 alkyl group or

b) a C_6 to C_{14} aryl group or

6) $R^{aN1}R^{aN2}N-R^{aM}-$, wherein R^{aM} represents

a) -CO-O- or

b) -CS-O-, provided that, in the leftmost bond a) or b) is bonded to the nitrogen atom, and

R^{aN1} and R^{aN2}, the same or different, independently represent

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a

substituent,

c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

d) an aliphatic C_2 to C_{22} acyl group which may have a substituent,

e) an aromatic C_7 to C_{15} acyl group which may have a substituent,

f) a C_6 to C_{14} aryl group which may have a substituent,

g) a 5-membered to 14-membered heteroaryl group which may have a substituent,

h) a C_7 to C_{22} aralkyl group which may have a substituent,

i) a C_1 to C_{22} alkylsulfonyl group which may have a substituent,

j) a C_6 to C_{14} arylsulfonyl group which may have a substituent,

k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN1} and R^{aN2} together in combination with the nitrogen atom to which R^{aN1} and R^{aN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

m) a C_3 to C_{14} cycloalkyl group which may have a substituent or

n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a

pharmacologically acceptable salt thereof, or a hydrate of those.

3. The compound according to claim 1 represented by the formula (I-b):



(I-b)

wherein W is the same as defined above, and R^{3b}, R^{7b}, R^{16b}, R^{17b}, R^{20b}, R^{21b} and $R^{21'b}$, the same or different, independently represent

1) a hydrogen atom,

2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R^{3b} or R^{7b} in combination with the carbon atom to which R^{3b} or R^{7b} is bonded, and an oxo group formed by R^{21b} and $R^{21b'}$ together in combination with the carbon atom to which R^{21b} and $R^{21b'}$ are bonded,

3) a C_1 to C_{22} alkoxy group which may have a substituent,

4) $R^bC(=O)-O-$, wherein R^b represents

a) a C_1 to C_{22} alkyl group which may have a substituent,

b) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

c) a C_7 to C_{22} aralkyl group which may have a

substituent,

d) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

e) a C_6 to C_{14} aryloxy group which may have a substituent,

f) a C_3 to C_{14} cycloalkyl group which may have a substituent or

g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

5) $R^{bS1}R^{bS2}R^{bS3}SiO-$, wherein R^{bS1}, R^{bS2} and R^{bS3}, the same or different, independently represent

a) a C_1 to C_6 alkyl group or

b) a C_6 to C_{14} aryl group or

6) $R^{bN1}R^{bN2}N-R^{bM}-$, wherein R^{bM} represents

a) -CO-O- or

b) -CS-O-, provided that, the leftmost bond in a) or b) is bonded to the nitrogen atom, and

R^{bN1} and R^{bN2}, the same or different, independently represent

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN1} and R^{bN2} together in combination with the nitrogen atom to which R^{bN1} and R^{bN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

d) a C_3 to C_{14} cycloalkyl group which may have

a substituent or

e) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

4. The compound according to claim 1 represented by the formula (I-c):



(I-c)

wherein W is the same as defined above, and R^{3c}, R^{7c}, R^{16c}, R^{17c}, R^{20c}, R^{21c} and $R^{21'c}$, the same or different, independently represent

1) a hydrogen atom,

2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R^{3c} or R^{7c} in combination with the carbon atom to which R^{3c} or R^{7c} is bonded, and an oxo group formed by R^{21c} and $R^{21c'}$ together in combination with the carbon atom to which R^{21c} and $R^{21c'}$ are bonded,

3) $R^cC(=O)-O-$, wherein R^c represents a C_1 to C_{22} alkyl group which may have a substituent,

4) $R^{cS1}R^{cS2}R^{cS3}SiO-$, wherein R^{cS1}, R^{cS2} and R^{cS3}, the same or different, independently represent

a) a C_1 to C_6 alkyl group or

b) a C_6 to C_{14} aryl group or

5) $R^{cN1}R^{cN2}N-R^{cM}-$, wherein R^{cM} represents -CO-O-, provided that the leftmost bond is bonded to the nitrogen atom, and

R^{cN1} and R^{cN2}, the same or different, independently represent

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{cN1} and R^{cN2} together in combination with the nitrogen atom to which R^{cN1} and R^{cN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

d) a C_3 to C_{14} cycloalkyl group which may have a substituent or

e) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

5. The compound according to claim 1 represented by the formula (I-d):



(I-d)

wherein R^{3d} and R^{16d}, the same or different, independently represent

1) a hydroxyl group,

2) a C_1 to C_{22} alkoxy group which may have a substituent,

3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

4) a C_7 to C_{22} aralkyloxy group which may have a substituent,

5) $R^dC(=O)-O-$, wherein R^d represents

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

d) a C_6 to C_{14} aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C_7 to C_{22} aralkyl group which may have a substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a C_1 to C_{22} alkoxy group which may have a substituent,

i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

j) a C_6 to C_{14} aryloxy group which may have a

substituent or

k) a 5-membered to 14-membered heteroaryloxy group which may have a substituent or

6) $R^{dN1}R^{dN2}N$-CO-O-, wherein R^{dN1} and R^{dN2}, the same or different, independently represent

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

d) a C_6 to C_{14} aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C_7 to C_{22} aralkyl group which may have a substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a C_3 to C_{14} cycloalkyl group which may have a substituent,

i) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

j) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{dN1} and R^{dN2} together in combination with the nitrogen atom to which R^{dN1} and R^{dN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and R^{7d} and R^{21d}, the same or different, independently

represent

1) a hydroxyl group,

2) a C_1 to C_{22} alkoxy group which may have a substituent,

3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

4) a C_7 to C_{22} aralkyloxy group which may have a substituent,

5) $R^dC(=O)-O-$, wherein R^d is the same as defined above,

6) $R^{dN1}R^{dN2}N-CO-O-$, wherein R^{dN1} and R^{dN2} are the same as defined above,

7) $R^{dN1}R^{dN2}N-SO_2-O-$, wherein R^{dN1} and R^{dN2} are the same as defined above,

8) $R^{dN1}R^{dN2}N-CS-O-$, wherein R^{dN1} and R^{dN2} are the same as defined above,

9) $R^{dN4}-SO_2-O-$, wherein R^{dN4} represents

a) a C_1 to C_{22} alkyl group which may have a substituent,

b) a C_6 to C_{14} aryl group which may have a substituent,

c) a C_1 to C_{22} alkoxy group which may have a substituent,

d) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

e) a C_6 to C_{14} aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C_7 to C_{22} aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

10) $(R^{dN5}O)_2PO-O-$, wherein R^{dN5} represents

a) a C_1 to C_{22} alkyl group which may have a substituent,

b) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

c) a C_6 to C_{14} aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,

e) a C_7 to C_{22} aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

11) $(R^{dN1}R^{dN2}N)_2PO-O-$, wherein R^{dN1} and R^{dN2} are the same as defined above or

12) $(R^{dN1}R^{dN2}N)(R^{dN5}O)PO-O-$, wherein R^{dN1}, R^{dN2} and R^{dN3} are the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate of those.

6. The compound according to claim 1, wherein R^7 and/or R^{21} are independently represented by $RC(=Y)-O-$, wherein Y and R are the same as defined above or $R^{N1}R^{N2}N-R^{M'}-$, wherein $R^{M'}$ represents

a) -CO-O- or

b) -CS-O-, provided that, the leftmost bond in a) or b) is bonded to the nitrogen atom, and

R^{N1} and R^{N2} are the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate of those.

7. The compound according to claim 5 represented by the formula (I-e):



(I-e)

wherein R^{3e}, R^{16e} and R^{21e}, the same or different, independently represent

1) a hydroxyl group,

2) a C_1 to C_{22} alkoxy group which may have a substituent,

3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

4) a C_7 to C_{22} aralkyloxy group which may have a substituent,

5) an aliphatic C_2 to C_6 acyl group which may have a substituent or

6) $R^{eN1}R^{eN2}N$-CO-O-, wherein R^{eN1} and R^{eN2} independently represent

a) a hydrogen atom or

b) a C_1 to C_6 alkyl group which may have a

substituent, and

R^{7e} represents R^e-C(=Y^e)-O-, wherein Y^e represents an oxygen atom or sulfur atom, and R^e, the same or different, represents

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) a C_6 to C_{14} aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,

e) a C_7 to C_{10} aralkyl group which may have a substituent,

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent

h) a group of the formula (III):



(III)

wherein A) n represents an integer of 0 to 4,

X_e represents

i) -CHR^{eN4}-,

ii) -NR^{eN5}-,

iii) -O-,

iv) -S-,

v) -SO- or

vi) $-SO_2-$,

R^{eN1} represents

i) a hydrogen atom or

ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{eN2} represents

i) a hydrogen atom or

ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{eN3} and R^{eN4}, the same or different, independently represent

i) a hydrogen atom,

ii) a C_1 to C_6 alkyl group which may have a substituent,

iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

iv) a C_6 to C_{14} aryl group which may have a substituent,

v) a 5-membered to 14-membered heteroaryl group which may have a substituent,

vi) a C_7 to C_{10} aralkyl group which may have a substituent,

vii) a C_3 to C_8 cycloalkyl group which may have a substituent,

viii) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl

group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

xi) $-NR^{eN6}R^{eN7}$, wherein R^{eN6} and R^{eN7}, the same or different, independently represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or

xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN3} and R^{eN4} together in combination with the carbon atom to which R^{eN3} and R^{eN4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and R^{eN5} represents

i) a hydrogen atom,

ii) a C_1 to C_6 alkyl group which may have a substituent,

iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

iv) a C_6 to C_{14} aryl group which may have a substituent,

v) a 5-membered to 14-membered heteroaryl group which may have a substituent,

vi) a C_7 to C_{10} aralkyl group which may have a substituent,

vii) a C_3 to C_8 cycloalkyl group which may have a substituent,

viii) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN3} and R^{eN5} together in combination with the nitrogen atom to which R^{eN3} and R^{eN5} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X_e, n, R^{eN3}, R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN1} and R^{eN2} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN1} and R^{eN2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

C)

X_e, n, R^{eN2}, R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN1} and R^{eN3} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN1} and R^{eN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

X_e, n, R^{eN1}, R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN2} and R^{eN3} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN2} and R^{eN3}

together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



(IV)

wherein R^{eN8} and R^{eN9}, the same or different, independently represent

i) a hydrogen atom,

ii) a C_1 to C_6 alkyl group which may have a substituent,

iii) a C_6 to C_{14} aryl group which may have a substituent,

iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,

v) a C_7 to C_{10} aralkyl group which may have a substituent or

vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

8. The compound according to claim 5, wherein R^{7e} and/or R^{21e} are independently represented by $R^{e1}C(=Y^{e1})-O-$, wherein Y^{e1} represents an oxygen atom or sulfur atom, and R^{e1} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a

substituent,

3) a C_6 to C_{10} aryl group which may have a substituent,

4) a 5-membered to 14-membered heteroaryl group which may have a substituent,

5) a C_7 to C_{10} aralkyl group which may have a substituent or

6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

9. The compound according to claim 5, wherein R^{7e} and/or R^{21e} are independently represented by $R^{e2}C(=Y^{e2})-O-$, wherein Y^{e2} represents an oxygen atom or sulfur atom, and R^{e2} represents a group of the formula (III'):



(III')

wherein A) n represents an integer of 0 to 4,

X_1 represents

1) $-CHR^{eN13}-$,

2) $-NR^{eN14}-$,

3) $-O-$,

4) $-S-$,

5) $-SO-$ or

6) $-SO_2-$,

R^{eN10} and R^{eN11}, the same or different, independently

represent

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent,

R^{eN12} and R^{eN13}, the same or different, independently represent

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_6 to C_{14} aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C_7 to C_{10} aralkyl group which may have a substituent,

7) a C_3 to C_8 cycloalkyl group which may have a substituent,

8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) $-NR^{eN15}R^{eN16}$, wherein R^{eN15} and R^{eN16}, the same or different, independently represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent,

or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN12} and R^{eN13} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

R^{eN14} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_6 to C_{14} aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C_7 to C_{10} aralkyl group which may have a substituent,

7) a C_3 to C_8 cycloalkyl group which may have a substituent,

8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) a 5-membered to 14-membered non-aromatic heterocyclic group formed together by the nitrogen atom to which R^{eN14} is bonded, and one substituent selected

from the group consisting of R^{eN10}, R^{eN11} and R^{eN12}, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed together by the nitrogen atom to which R^{eN14} is bonded, and two substituents selected from the group consisting of R^{eN10}, R^{eN11} and R^{eN12}, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

B)

n, X_1, R^{eN11}, R^{eN13} and R^{eN14} are the same as defined above, and R^{eN10} and R^{eN12} together form a 5-membered to 14-membered non-aromatic heterocyclic group, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

10. The compound according to claim 5, wherein X_1 represents $-NR^{eN14}-$, wherein NR^{eN14} is the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate of those.

11. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e3}C(=Y^{e3})-O-$, wherein Y^{e3} represents an oxygen atom or sulfur atom, and R^{e3} represents a group of the formula (V):



(V)

wherein n_1 represents an integer of 0 to 6,

R^{eN17} represents

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent, and

R^{eN18} represents

1) a hydrogen atom,

2) an amino group which may have a substituent,

3) a pyridyl group which may have a substituent,

4) a pyrrolidin-1-yl group which may have a substituent,

5) a piperidin-1-yl group which may have a substituent,

6) a morpholin-4-yl group which may have a substituent or

7) a piperazin-1-yl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

12. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e4}CO-O-$, wherein R^{e4} represents a group of the formula (VI):



(VI)

wherein n_2 and n_3, the same or different, independently represent an integer of 0 to 4,

X_2 represents

1) $-CHR^{eN21}-$,

2) $-NR^{eN22}-$,

3) $-O-$,

4) $-S-$,

5) $-SO-$ or

6) $-SO_2-$,

R^{eN19} represents

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent,

R^{eN20} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) a C_6 to C_{14} aryl group which may have a substituent or

4) a C_7 to C_{10} aralkyl group which may have a substituent,

R^{eN21} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a

substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_6 to C_{14} aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C_7 to C_{10} aralkyl group which may have a substituent,

7) a C_3 to C_8 cycloalkyl group which may have a substituent,

8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) $-NR^{eN23}R^{eN24}$, wherein R^{eN23} and R^{eN24}, the same or different, independently represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or

11) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{eN22} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_6 to C_{14} aryl group which may have a

substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C_7 to C_{10} aralkyl group which may have a substituent,

7) a C_3 to C_8 cycloalkyl group which may have a substituent,

8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

13. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e5}CO-O-$, wherein R^{e5} represents a group of the formula (VII):



(VII)

wherein n_4 represents 1 or 2,

R^{eN25} represents

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent, and

R^{eN26} represents

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

14. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e6}CO-O-$, wherein R^{e6} represents a group of the formula (VIII):



(VIII)

wherein n_2 and n_3, the same or different, independently represent an integer of 0 to 4,

X_3 represents

1) $-CHR^{eN29}-$,

2) $-NR^{eN30}-$,

3) $-O-$,

4) $-S-$,

5) $-SO-$ or

6) $-SO_2-$,

R^{eN27} represents

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent,

R^{eN28} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) a C_6 to C_{14} aryl group which may have a substituent or

4) a C_7 to C_{10} aralkyl group which may have a substituent,

R^{eN29} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_1 to C_6 alkoxy group which may have a substituent,

5) a C_6 to C_{14} aryl group which may have a substituent,

6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C_7 to C_{10} aralkyl group which may have a substituent,

8) a C_3 to C_8 cycloalkyl group which may have a substituent,

9) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

10) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

11) $-NR^{eN31}R^{eN32}$, wherein R^{eN31} and R^{eN32}, the same or different, independently represent a hydrogen atom

or a C_1 to C_6 alkyl group which may have a substituent, or form a 5-membered to 14-membered non-aromatic heterocyclic group together with the nitrogen atom to which R^{eN31} and R^{eN32} are bonded or

12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{eN30} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_6 to C_{14} aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C_7 to C_{10} aralkyl group which may have a substituent,

7) a C_3 to C_8 cycloalkyl group which may have a substituent,

8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

15. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e7}CO-O-$, wherein R^{e7} represents a group of the formula (IX):



(IX)

wherein n_5 represents an integer of 1 to 3, and R^{eN33} represents

1) an amino group,

2) an amino group which may have a substituent,

3) a pyrrolidin-1-yl group which may have a substituent,

4) a piperidin-1-yl group which may have a substituent or

5) a morpholin-4-yl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

16. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e8}CO-O-$, wherein R^{e8} represents a group of the formula (X):



(X)

wherein n_5 represents an integer of 1 to 3,

R^{eN34} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) a C_6 to C_{14} aryl group which may have a substituent or

4) a C_7 to C_{10} aralkyl group which may have a substituent, and

R^{eN35} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) a C_3 to C_8 cycloalkyl group which may have a substituent,

4) a 3-membered to 8-membered non-aromatic heterocyclic group which may have a substituent,

5) a C_6 to C_{14} aryl group which may have a substituent,

6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C_7 to C_{10} aralkyl group which may have a substituent,

8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

9) a C_4 to C_9 cycloalkylalkyl group which may have a substituent; a pharmacologically acceptable salt

thereof, or a hydrate of those.

17. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e9}CO-O-$, wherein R^{e9} represents a group of the formula (XI):



(XI)

wherein n_5 represents an integer of 1 to 3, and R^{eN36} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) a C_3 to C_8 cycloalkyl group which may have a substituent,

4) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

5) a C_7 to C_{10} aralkyl group which may have a substituent,

6) a pyridyl group which may have a substituent or

7) a tetrahydropyranyl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

18. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e10}CO-O-$, wherein

R^{e10} represents a group of the formula (XII):



(XII)

wherein m_1, m_2, m_3, and m_4, the same or different, independently represent 0 or 1,

n_5 represents an integer of 1 to 3, and

R^{eN37} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_6 to C_{14} aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C_7 to C_{10} aralkyl group which may have a substituent,

7) a C_3 to C_8 cycloalkyl group which may have a substituent,

8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic

heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those.

19. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e11}CO-O-$, wherein R^{e11} represents a group of the formula (XIII):



(XIII)

wherein m_5 represents an integer of 1 to 3, and n_5 represents 2 or 3; a pharmacologically acceptable salt thereof, or a hydrate of those.

20. The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e12}CO-O-$, wherein R^{e12} represents a group selected from a group consisting of:



and



, or a group selected from a group consisting of

and

, and

both of which may have a substituent on the ring; a pharmacologically acceptable salt thereof, or a hydrate of those.

21. The compound according to claim 1, wherein R^{16} is a hydroxyl group; a pharmacologically acceptable salt thereof, or a hydrate of those.

22. The compound according to claim 1, wherein

[1] W is



R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16}, R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom,

[2] W is



R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16}, R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom,

[3] W is



R^3, R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom,

[4] W is



R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded, R^3, R^{16} and R^{20} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} is a hydrogen atom,

[5] W is



R^3, R^{16}, R^{20} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and $R^{21'}$ are a hydrogen atom,

[6] W is



R^3, R^7, R^{16} and R^{21} are a hydroxyl group, and R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom,

[7] W is



R^3, R^{17}, R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{20} and $R^{21'}$ are a hydrogen atom or

[8] W is



R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded, R^3 and R^{16} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and R^{20} are a hydrogen atom; a pharmacologically acceptable salt thereof, or a hydrate of those.

23. The compound according to claim 1, which is (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylhomopiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-(piperidin-1-yl)piperidin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-7-((4-ethylpiperazin-1-yl)carbonyl)oxy-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide, (8E,12E,14E)-7-(N-(3-(N',N'-dimethylamino)propyl)-N-methylcarbamoyloxy)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-

pentamethyl-7-((piperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(N-methyl-N-(1-methylpiperidin-4-yl)carbamoyloxy)-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylhomopiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-((4-(4-hydroxypiperidin-1-yl)piperidin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-(morpholin-4-yl)piperidin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-7-((4-ethylhomopiperazin-1-yl)carbonyl)oxy-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylpiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-(((1S,4S)-5-isopropyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-7-(N-(2-(N',N'-dimethylamino)ethyl)-N-methylcarbamoyloxy)-3,16,21-

trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-7-(N-(2-(N',N'-dimethylamino)ethyl)carbamoyloxy)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide or

(8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide.

24. The compound according to claim 1, which is (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(N-methyl-N-(1-methylpiperidin-4-yl)carbamoyloxy)-18,19-epoxytricosa-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylhomopiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide, (8E,12E,14E)-7-((4-ethylhomopiperazin-1-yl)carbonyl)oxy-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylpiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide or (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)carbonyl)oxy-18,19-

epoxytricosa-8,12,14-trien-11-olide.

25. A medicine comprising the compound according to any one of claims 1 to 24, a pharmacologically acceptable salt thereof, or a hydrate of those as an active ingredient.

26. A pharmaceutical composition comprising the compound according to any one of claims 1 to 24, a pharmacologically acceptable salt thereof, or a hydrate of those as an active ingredient.

27. The medicine according to claim 25 as an agent for preventing or treating a disease for which gene expression control is effective.

28. The medicine according to claim 25 as an agent for preventing or treating a disease for which suppression of VEGF production is effective.

29. The medicine according to claim 25 as an agent for preventing or treating a disease for which an antiangiogenic effect is effective.

30. The medicine according to claim 25 as an angiogenesis inhibitor.

31. The medicine according to claim 25 as an

antitumor agent.

32. The medicine according to claim 25 as a therapeutic agent for treating hemangioma.

33. The medicine according to claim 25 as a cancer metastasis inhibitor.

34. The medicine according to claim 25 as a therapeutic agent for treating retinal neovascularization or diabetic retinopathy.

35. The medicine according to claim 25 as a therapeutic agent for treating inflammatory disease.

36. The medicine according to claim 25 as a therapeutic agent for inflammatory diseases consisting of deformant arthritis, rheumatoid arthritis, psoriasis, and delayed hypersensitive reaction.

37. The medicine according to claim 25 as a therapeutic agent for treating atherosclerosis.

38. The medicine according to claim 25 as a therapeutic agent for treating a solid cancer.

39. The medicine according to claim 38, wherein the solid tumor is lung cancer, brain tumor, breast

cancer, prostate cancer, ovarian cancer, colon cancer or melanoma.

40. The medicine according to claim 25 as a therapeutic agent for treating leukemia.

41. The medicine according to claim 25 as an antitumor agent based on gene expression control.

42. The medicine according to claim 25 as an antitumor agent based on suppression of VEGF production.

43. The medicine according to claim 25 as an antitumor agent based on an effect of angiogenesis inhibition.

44. A method for preventing or treating a disease for which gene expression control is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 25 to a patient.

45. A method for preventing or treating a disease for which suppression of VEGF production is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 25 to a patient.

46. A method for preventing or treating a disease for which angiogenesis inhibition is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 25 to a patient.

47. Use of the compound according to any one of claims 1 to 24, a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which gene expression control is effective.

48. Use of the compound according to any one of claims 1 to 24, a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which suppression of VEGF production is effective.

49. Use of the compound according to any of claims 1 to 24, a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which angiogenesis inhibition is effective.

50. Use of the compound according to any one of claims 1 to 24, a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an

agent for preventing or treating a solid cancer.

51. A method for producing a 6-deoxy 11107 compound, characterized in that the method comprises culturing a microorganism belonging to the genus Streptomyces, which is capable of producing a compound of the formula (I):



(I)

wherein [1] W is



R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16}, R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom or

[2] W is



R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16}, R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom; and collecting the compound as defined in [1] or [2] (hereinafter referred to as "6-deoxy 11107 compound") from the culture.

52. Streptomyces sp. strain A-1543 (FERM BP-8442) that is capable of producing the 6-deoxy 11107 compound according to claim 51.

53. A method for producing a 6-deoxy compound by biologically converting a compound of the formula (I):



(I)

wherein [1] W is



R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16}, R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom (hereinafter referred to as "6-deoxy 11107B") into a compound of the formula (I), wherein

[3] W is



R^3, R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom,

[4] W is



R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded, R^3, R^{16} and R^{20} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} is a hydrogen atom,

[5] W is



R^3, R^{16}, R^{20} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and $R^{21'}$ are a hydrogen atom,

[6] W is



R^3, R^7, R^{16} and R^{21} are a hydroxyl group, and R^{17}, R^{20} and $R^{21'}$ are a hydrogen atom,

[7] W is



R^3, R^{17}, R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{20} and $R^{21'}$ are a hydrogen atom or

[8] W is



R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded, R^3 and R^{16} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and R^{20} are a hydrogen atom (these compounds are hereinafter referred to as "6-deoxy compounds"), comprising
1) a step that can conduct the biological conversion, the step of incubating 6-deoxy 11107B in the presence of a culture solution of a strain selected from microorganisms belonging to bacteria or a product prepared from culture cells of the strain, and
2) collecting a 6-deoxy compound from the incubated solution.

54. The method according to claim 53, wherein the microorganism belonging to bacteria is strain A-1544 (FERM BP-8446) or strain A-1545 (FERM BP-8447).

55. Strain A-1544 (FERM BP-8446) or strain A-1545 (FERM BP-8447) which is capable of converting 6-deoxy 11107B into a 6-deoxy compound.